Last €0.01 EUR
Change Today +0.003 / 37.50%
Volume 0.0
DU8 On Other Exchanges
Symbol
Exchange
OTC US
Frankfurt
As of 2:12 AM 05/3/16 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

60-66 Hanover Street

Fitzroy, VIC 3065

Australia

Phone: 61 3 8412 7000

Fax: 61 3 8412 7040

Genetic Technologies Limited operates as a biotechnology company. BREVAGen The company offers a proprietary breast cancer risk assessment test named BREVAGen. In addition to the BREVAGen test, the company owns a suite of patents valid to 2022, which augment and extend the company’s non-coding patent portfolio. In 2010, the company incorporated a wholly-owned subsidiary named Phenogen Sciences Inc. in the state of Delaware, which commenced selling the BREVAGen test in the U.S. marketplace in 2011. In 2014, the company announced the U.S. release of BREVAGenplus, a predictive risk test for various women at risk of developing sporadic, or non-hereditary, breast cancer, representing a marked enhancement in patient applicability, over the company’s first generation BREVAGen product. BREVAGenplus is a clinically validated, predictive risk test for sporadic breast cancer which examines a woman’s clinical risk factors, combined with 77 scientifically validated genetic biomarkers, to allow for more personalized breast cancer risk assessment and risk management. The strategic alliance with Myriad Genetics Inc. delivered to the company exclusive rights in Australia and New Zealand to perform DNA testing for susceptibility to a range of cancers. The company would continue to pursue out-licensing/co-development partnering options for the RareCellect Project. Environmental Regulations The company’s operations are subject to environmental regulations under Australian State legislation. In particular, the company is subject to the requirements of the Environment Protection Act 1993. Dispositions In 2014, the company completed the sale of its heritage Australian Genetics business to Specialist Diagnostic Services Ltd. Strategy As part of the company’s strategy to focus on the expansion of its cancer diagnostic franchise, the company continues to evaluate opportunities to sell, out-license or co-develop other assets and technologies in which the company has an interest, including its legacy non-coding assertion and licensing program. History Genetic Technologies Limited was founded in 1989.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DU8:GR €0.01 EUR +0.003

DU8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Agilent Technologies Inc $41.24 USD -0.47
Sonic Healthcare Ltd A$20.27 AUD +0.53
View Industry Companies
 

Industry Analysis

DU8

Industry Average

Valuation DU8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 31.3x
Price/Book 2.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 18.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact GENETIC TECHNOLOGIES LTD, please visit www.gtglabs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.